Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer. - Wikidata - wikimedia - TriplyDB

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.

http://www.wikidata.org/entity/Q37220528

about

Profile of farletuzumab and its potential in the treatment of solid tumors Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma.Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer Targeted treatment of folate receptor-positive platinum-resistant ovarian cancer and companion diagnostics, with specific focus on vintafolide and etarfolatide.Role of Wnt/β-catenin, Wnt/c-Jun N-terminal kinase and Wnt/Ca2+ pathways in cisplatin-induced chemoresistance in ovarian cancer.Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer.Inhibition of paclitaxel resistance and apoptosis induction by cucurbitacin B in ovarian carcinoma cells.Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors.Activation of hedgehog signaling and its association with cisplatin resistance in ovarian epithelial tumors.

P2860

Q26750431-FBA74C6C-973F-4291-A324-BD99C3C465CE Q35051870-78CF91A7-DD09-4343-87A7-189E16A542B7 Q37510967-E851A27C-5BF2-46AB-B7FD-1B7C7FA3A9A3 Q37567078-B275F642-256D-48A6-8B2F-C8D7697DD41D Q37582011-A8729194-D47D-43CE-BF08-D563F2676CC9 Q37685630-7092FA45-D932-4B5A-B2D2-215854C10C5D Q38697712-8364D785-08D3-4412-9465-4A0B8E020590 Q42373834-809C6008-7E21-4E74-BE3C-CF9B603A712C Q52649683-A7841DB5-A8A3-4458-BF4F-B46D656E1400

P2860

Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.

http://www.wikidata.org/entity/Q37220528

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 25 September 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Patient selection and targeted ...... inum-resistant ovarian cancer.

@en

Patient selection and targeted ...... inum-resistant ovarian cancer.

@nl

type

label

Patient selection and targeted ...... inum-resistant ovarian cancer.

@en

Patient selection and targeted ...... inum-resistant ovarian cancer.

@nl

prefLabel

Patient selection and targeted ...... inum-resistant ovarian cancer.

@en

Patient selection and targeted ...... inum-resistant ovarian cancer.

@nl

P1433

Q37220528-F6546C79-297C-4FE5-BD8D-7ED3331BE665

P1476

Q37220528-A2FD003D-46B5-42AB-9937-6494CC80F26B

P2093

Q37220528-3D0A565A-72C2-44B0-AFC5-AE98AD1BCB1F

Q37220528-7DED48CB-7C7E-4F36-BEDB-E35405789014

Q37220528-A836308A-C415-4005-9762-E11478FD2794

P2860

Q37220528-00F887F0-6A3B-4C16-829F-CC218F9F884C

Q37220528-0D8BFAAC-9E4D-417A-8D9D-8033511D95FA

Q37220528-0F054926-B546-42B0-9B63-15BE84704181

Q37220528-124D7CC2-5C65-4157-B504-7FEBE1045416

Q37220528-1DEAAF26-1FB7-4D50-AF95-0BD4515D1867

Q37220528-236E9D11-92BD-4E6E-8AEC-1E9F1F283DB0

Q37220528-29013114-93B5-48CC-8C7A-4D821847922D

Q37220528-35110C1D-1234-4712-9442-C1DFF8B5BC43

Q37220528-36FB3377-91FF-4094-8244-FC6625ECF078

Q37220528-39319981-87A5-4DB4-88C2-90A8E7CBA969

P304

Q37220528-94870688-CBC2-4E57-B4D7-B18BF8592604

P31

Q37220528-2E4B4F90-9645-46F0-8AD8-0D2FB976D341

P356

Q37220528-ED81FC87-4B6B-4FE8-9A45-D96C91ECEC1C

P478

Q37220528-65CC7794-8727-478A-8611-73DC08FB4ADA

P577

Q37220528-8E002CD8-653E-4B08-9490-43BE3EE788E7

P5875

Q37220528-D9DB19FB-066E-4245-990E-34C5757DDEA6

P698

Q37220528-58FECE91-BBD5-47D2-B557-49CF032DBF5A

P921

Q37220528-88FC537D-A411-471A-BF80-AB6DBE93E0F9

Q37220528-E375A59E-E46E-4288-B612-F10A40436018

P932

Q37220528-8E708341-8B0F-4306-A128-5A7FB6B81FA9

P356

P1433

Pharmacogenomics and Personalized Medicine

P1476

Patient selection and targeted ...... inum-resistant ovarian cancer.

@en

P2093

Binh Nguyen

http://www.w3.org/2001/XMLSchema#string

Chandra D Lovejoy

http://www.w3.org/2001/XMLSchema#string

Christopher P Leamon

http://www.w3.org/2001/XMLSchema#string

P2860

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Cancer statistics, 2013

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.

Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.

Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy.

P304

113-125

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PGPM.S24943

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2013-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257600071

http://www.w3.org/2001/XMLSchema#string

P698

24109193

http://www.w3.org/2001/XMLSchema#string

P921

P932

3792616

http://www.w3.org/2001/XMLSchema#string